BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors. The patients were evaluated under normal clinical practice and were asked to fill out the quality of life FAMS questionnaire, Coping processes (WCQ - Ways of Coping Questionnaire) and depression questionnaire CES-D.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Relapsing-remitting MS (RRMS) or secondary-progressive MS (SPMS)

• Previous treatment with disease modifying drugs

• Adjustment of disease modifying treatment necessary at the discretion of the investigator

• Switch to Betaferon at least 1 month but not longer than 3 months prior to inclusion

Exclusion Criteria:

• Patients not fulfilling the indications in the local prescribing information

• Refusal to sign inform consent